Last reviewed · How we verify
CBM588 Capsules
At a glance
| Generic name | CBM588 Capsules |
|---|---|
| Also known as | CBM588, Clostridium butyricum MIYAIRI 588, C. butyricum MIYAIRI 588, C. butyricum strain MIYAIRI 588 |
| Sponsor | Osel, Inc. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Clostridium Butyricum in Stenosing Crohn's Desease (PHASE1, PHASE2)
- CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CBM588 Capsules CI brief — competitive landscape report
- CBM588 Capsules updates RSS · CI watch RSS
- Osel, Inc. portfolio CI